This study provides compelling evidence for the neuroprotective effects of G9a inhibition combined with cannabinoid receptor activation in AD, offering a multifaceted therapeutic approach to address cognitive decline and neurodegeneration. The gene discussed is EHMT2; the disease is Alzheimer disease.